Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
107.72
(
-0.49%
)
Bitcoin
67,227.47
(
1.92%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ThomasS post# 57294

Thursday, 01/10/2008 6:46:11 PM

Thursday, January 10, 2008 6:46:11 PM

Post# of 257302
>IDIX: Are you actively selling into this, or holding the bulk?<

I haven’t sold any IDIX shares.

What some people may have forgotten about IDIX is that it’s a bona fide drug-discovery company, and this is one of the reasons NVS paid big money to acquire a majority stake. As a result, IDIX has always had internally-generated backup compounds in HCV to bring forward in the event that NM283 didn’t work out. This is in contrast to “virtual” biotech companies that have to go out and in-license something new if a drug candidate flops.

The future SoC in HCV will almost certainly include at least one nucleoside/nucleotide, and there are now only two nukes ahead of IDX184 (R7128 and R1626). So this is itself a pretty big opportunity for a company that the market had left for dead.

The HIV opportunity is also compelling, IMO. If the head-to-head trial vs Sustiva (Truvada+IDX899 vs Truvada+Sustiva) works out, IDIX ought to be able to ink a very lucrative partnership deal (#msg-25885594).

Moreover, Tyzeka could still generate significant royalty income for IDIX if NVS can figure out how to position it in the growing HBV arena.

Last but not least, you get $100M+ of cash on the balance sheet with no debt.

What’s not to like?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today